Flamel Technologies is developing Genvir (formerly known as Viropump), a twice-daily controlled-release formulation of aciclovir, for potential use in the treatment of herpes simplex virus and varicella zoster virus infections. Genvir utilizes Flamel's proprietary Micropump technology, a microparticle-based drug delivery system designed to extend the time of absorption of drugs in the small intestine. The drug shows a comparable therapeutic efficacy to valaciclovir and famciclovir (both GlaxoSmithKline) . Phase III trials have been completed . In August 2000, Flamel filed for regulatory approval for the treatment of herpes in France, as a prelude to a pan-European approval  and is preparing an IND application to begin clinical trials for genital herpes in the US .
Barnard, D.L. 2001. Genvir. Curr. Opin. Investig. Drugs. 2: 622-623. PMID: 11569934